Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. more
Time Frame | PCSA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.03% | 0.31% | -1.26% |
1-Month Return | -20.56% | 0.6% | -4.16% |
3-Month Return | -33.37% | -9.44% | -0.46% |
6-Month Return | -52.52% | -5.15% | 3.58% |
1-Year Return | -84.11% | 0.33% | 22.47% |
3-Year Return | -99.05% | 4.53% | 25.13% |
5-Year Return | -99.77% | 35.98% | 77.7% |
10-Year Return | -99.96% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 877.90K | 15.14M | 12.13M | 27.53M | 222.00 | [{"date":"2019-12-31","value":3.19,"profit":true},{"date":"2020-12-31","value":54.99,"profit":true},{"date":"2021-12-31","value":44.08,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | (877.90K) | (15.14M) | (12.13M) | (27.53M) | (222.00) | [{"date":"2019-12-31","value":-87789700,"profit":false},{"date":"2020-12-31","value":-1513685900,"profit":false},{"date":"2021-12-31","value":-1213354300,"profit":false},{"date":"2022-12-31","value":-2752543100,"profit":false},{"date":"2023-12-31","value":-22200,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 3.94M | 6.44M | 11.57M | 20.26M | 11.46M | [{"date":"2019-12-31","value":19.43,"profit":true},{"date":"2020-12-31","value":31.78,"profit":true},{"date":"2021-12-31","value":57.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":56.56,"profit":true}] |
Operating Income | (3.94M) | (15.14M) | (12.13M) | (27.53M) | (11.46M) | [{"date":"2019-12-31","value":-393548200,"profit":false},{"date":"2020-12-31","value":-1513685900,"profit":false},{"date":"2021-12-31","value":-1213354300,"profit":false},{"date":"2022-12-31","value":-2752543100,"profit":false},{"date":"2023-12-31","value":-1145706100,"profit":false}] |
Total Non-Operating Income/Expense | (50.22K) | (555.90K) | 187.03K | 202.40K | 662.09K | [{"date":"2019-12-31","value":-7.59,"profit":false},{"date":"2020-12-31","value":-83.96,"profit":false},{"date":"2021-12-31","value":28.25,"profit":true},{"date":"2022-12-31","value":30.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (3.96M) | (15.41M) | (11.96M) | (27.42M) | (11.12M) | [{"date":"2019-12-31","value":-396059200,"profit":false},{"date":"2020-12-31","value":-1541480700,"profit":false},{"date":"2021-12-31","value":-1195814500,"profit":false},{"date":"2022-12-31","value":-2742422900,"profit":false},{"date":"2023-12-31","value":-1112152000,"profit":false}] |
Income Taxes | (602.72K) | (1.00M) | (530.61K) | 27.42M | (2.00) | [{"date":"2019-12-31","value":-2.2,"profit":false},{"date":"2020-12-31","value":-3.65,"profit":false},{"date":"2021-12-31","value":-1.93,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (3.36M) | (14.41M) | (11.43M) | (54.85M) | (11.12M) | [{"date":"2019-12-31","value":-335787600,"profit":false},{"date":"2020-12-31","value":-1441378800,"profit":false},{"date":"2021-12-31","value":-1142753400,"profit":false},{"date":"2022-12-31","value":-5484845800,"profit":false},{"date":"2023-12-31","value":-1112151800,"profit":false}] |
Income From Continuous Operations | (3.36M) | (14.41M) | (11.43M) | (27.42M) | (21.73M) | [{"date":"2019-12-31","value":-335787600,"profit":false},{"date":"2020-12-31","value":-1441378800,"profit":false},{"date":"2021-12-31","value":-1142753400,"profit":false},{"date":"2022-12-31","value":-2742422900,"profit":false},{"date":"2023-12-31","value":-2172890900,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.36M) | (14.41M) | (11.43M) | (54.85M) | (11.12M) | [{"date":"2019-12-31","value":-335787600,"profit":false},{"date":"2020-12-31","value":-1441378800,"profit":false},{"date":"2021-12-31","value":-1142753400,"profit":false},{"date":"2022-12-31","value":-5484845800,"profit":false},{"date":"2023-12-31","value":-1112152000,"profit":false}] |
EPS (Diluted) | (3.29) | (2.53) | (0.74) | (1.25) | (2.06) | [{"date":"2019-12-31","value":-328.8,"profit":false},{"date":"2020-12-31","value":-253,"profit":false},{"date":"2021-12-31","value":-74,"profit":false},{"date":"2022-12-31","value":-125,"profit":false},{"date":"2023-12-31","value":-205.7,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
PCSA | |
---|---|
Cash Ratio | 2.37 |
Current Ratio | 3.97 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
PCSA | |
---|---|
ROA (LTM) | -113.11% |
ROE (LTM) | -211.71% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
PCSA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.25 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
PCSA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.73 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Processa Pharmaceuticals Inc (PCSA) share price today is $0.8262
Yes, Indians can buy shares of Processa Pharmaceuticals Inc (PCSA) on Vested. To buy Processa Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PCSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Processa Pharmaceuticals Inc (PCSA) via the Vested app. You can start investing in Processa Pharmaceuticals Inc (PCSA) with a minimum investment of $1.
You can invest in shares of Processa Pharmaceuticals Inc (PCSA) via Vested in three simple steps:
The 52-week high price of Processa Pharmaceuticals Inc (PCSA) is $7.14. The 52-week low price of Processa Pharmaceuticals Inc (PCSA) is $0.8.
The price-to-earnings (P/E) ratio of Processa Pharmaceuticals Inc (PCSA) is
The price-to-book (P/B) ratio of Processa Pharmaceuticals Inc (PCSA) is 0.73
The dividend yield of Processa Pharmaceuticals Inc (PCSA) is 0.00%
The market capitalization of Processa Pharmaceuticals Inc (PCSA) is $2.70M
The stock symbol (or ticker) of Processa Pharmaceuticals Inc is PCSA